ARS Pharmaceuticals, Inc. reported 2025 revenues of $84.3m, a net loss of $171.3m, and plans to sustain high SG&A spending.

Thank you, Anthony. 2025 was a defining year of excellent execution and portfolio expansion at Amneal Pharmaceuticals, Inc.

A weak result and a sudden CEO departure have left CSL shares at eight-year lows. Management says the recovery plan ... Read More The post Dr Boreham’s Crucible: CSL’s tough diagnosis appeared first ...

The Prefilled Auto Injectors Market is poised for robust expansion driven by escalating incidence of chronic conditions, heightened demand for self-administration therapeutics, and intensifying focus ...

U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short ...

Barclays 28th Annual Global Healthcare Conference March 10, 2026 8:00 PM EDTCompany ParticipantsWilliam Peters - ...

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some ...